Merck's Keytruda fails late-stage trial as standalone treatment for breast cancer

In a late-stage clinical trial testing Merck's blockbuster cancer drug Keytruda as a standalone treatment for triple-negative breast cancer patients, the drug failed to meet its goal of boosting overall survival, according to Endpoints News.

The 622 patients in the trial were  given Keytruda or chemotherapy.. The patients given Keytruda fared no better in terms of survival than the patients receiving chemotherapy.

Merck plans to continue to test Keytruda as a monotherapy in earlier stages of the disease and in combination with chemotherapy for the aggressive type of breast cancer.

Keytruda is approved in the U.S. for other forms of cancer, including skin and lung.

Read the full report here.

More articles on pharmacy:
CMS targets spread pricing in new guidance
The Met turns down gifts from Purdue Pharma's Sackler family
CVS to test all vitamins, supplements

© Copyright ASC COMMUNICATIONS 2020. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.


Featured Content

Featured Webinars

Featured Whitepapers